The quality Chinese medicinal materials defined in this document refer to those that are produced in accordance with the Good Practice for Chinese Medicinal Materials Production (GAP) and Good Practice for Planting and Harvesting of Medicinal Plants (GACP) and other management regulations. The Chinese medicinal materials indicators are higher than the indicators of the Chinese Pharmacopoeia (2020 edition), and the limit indicators of exogenous pollutants and endogenous toxic substances are lower than the indicators of the Chinese Pharmacopoeia (2020 edition). The series of standards including this document also add exclusive technical methods according to specific varieties to formulate quality control standards that can reflect the intrinsic quality. The quality standards of quality artemisinin medicinal materials add the content detection of the main ingredient artemisinin, the limit of exogenous pollutants (pesticide residues, heavy metals and harmful elements, mycotoxins, etc.), and improve the limit standards of extracts, including sources, properties, identification indicators, inspection indicators, extracts, index (effective) ingredient content, pesticide residues, heavy metals, mycotoxins, etc. This standard is higher than the current Chinese Pharmacopoeia (2020 edition), and it is effectively supplemented and improved to make its quality better than that of qualified artemisia annua medicinal materials.
T/CAQ 29008-2023 history
2023T/CAQ 29008-2023 Quality Chinese medicinal materials—Artemisiae annuae herba